FDA Approves New Treatments for Three Cancer Types
In November and the first half of December, the U.S. Food and Drug Administration (FDA) announced three approvals for...
Category: Policy
In November and the first half of December, the U.S. Food and Drug Administration (FDA) announced three approvals for...
As 2019 draws to a close, the American Association for Cancer Research (AACR) is grateful for our growing ranks...
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United...
The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S....
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry. Panelists...
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted...
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...